Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
A phase 3 trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence and improved survival. Patients who received multi-session treatment lived nine months longer than those treated in a single session without significantly increasing side effects.
Researchers found implanting collagen tiles during brain surgery to deliver targeted radiation therapy improves tumor control, lowers recurrence risk, and increases overall survival. Patients treated with tile-based radiation therapy had a 1.3% rate of recurrence at the surgical site compared to 15.4% in the control group.
Patients with small cell lung cancer and brain metastases lived 17.4 months with radiosurgery, compared to 8.6 months with whole brain treatment. Radiosurgery was associated with a 40% lower risk of death. The study challenges the long-standing reliance on whole brain treatment for SCLC brain metastases.
A Phase III trial found that delivering focused radiation therapy over three to five sessions after surgery for a large brain metastasis reduced cancer recurrence at the surgical site. Fractionated stereotactic radiosurgery also showed a trend in controlling brain metastases that had not been removed surgically. Median overall survival...
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers at the University of Maryland Baltimore County have identified USP15 as a promising new target for ovarian cancer treatment, which appears to rely on the enzyme for survival, division, and spread. Reducing USP15 levels makes cancer cells more sensitive to chemotherapy drugs, potentially leading to less harm to healthy cells.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
A preclinical study found that SIRPα, a protein regulating immune cells, helps triple-negative breast cancer cells spread to the brain and weaken the immune response. Higher levels of SIRPα were associated with poorer outcomes in patients with TNBC, which is an aggressive form of breast cancer prone to brain metastasis.
Researchers discovered that cancer cells with RET mutations produce higher levels of the OPG protein, which disrupts bone renewal and blocks destruction, favoring bone accumulation. Measuring OPG levels via blood tests could identify and monitor patients with aggressive disease.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Researchers at MSK have identified a protein called integrin alpha-5 as a key driver of lung metastasis across several cancer types. A new three-drug combination that includes epcoritamab, rituximab, and lenalidomide is effective in almost all patients newly diagnosed with follicular lymphoma, offering a potential alternative to chemot...
Researchers at the University of Massachusetts Amherst have been awarded $2.5 million to adapt their nanoparticle vaccine research to treat existing cancer. The prime-pull approach will deliver immune-activating medicines to both lymph nodes and tumors to create a robust immune response.
Researchers found that radiation to the thymus during NSCLC treatment increased cancer spread and mortality risk in patients with relatively healthy thymus. Thymic health scores were associated with T-cell diversity, longevity, and cancer outcomes.
Researchers at the University of Turku discovered a molecular mechanism that regulates the spread of aggressive colorectal cancer. The mechanism involves the secretion of mucus onto the surface of tumour spheres, which facilitates their migration and invasion of tissue.
Researchers have identified a molecular switch driving the spread of aggressive triple-negative breast cancer, a subtype with poor outcomes. Restoring a naturally occurring molecule called miR-342 reduced metastatic disease in pre-clinical models.
A team of researchers at Columbia University has developed a multi-organ chip that mimics the process of cancer cells spreading to other organs, a critical phase of metastasis. The chip allows scientists to investigate cancer cell-tissue interactions in detail, revealing molecular pathways and therapeutic targets for metastasis.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
The study identified RTN4IP1 as a factor associated with poor prognosis in triple-negative breast cancer, promoting metastasis through NAD⁺ depletion and disrupting glycolysis and oxidative phosphorylation. RTN4IP1 interacts with AK4 to cause this metabolic disruption.
A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is associated with improved patient survival, and this cutoff may be the best metric for determining treatment success, according to investigators analyzing Veterans Health Administration data.
A new study identified a previously underappreciated relationship between SUCLA2 and USP10 that strongly correlates with distant metastasis-free survival in breast cancer patients. The interaction between these two genes changes dramatically depending on whether patients receive treatment, highlighting the importance of considering mol...
A digital treatment concept, PRO B, combines close monitoring via an app with on-demand in-person care to alleviate fatigue and improve daily life for patients with metastatic breast cancer. The approach has been shown to reduce exhaustion, improve physical functioning, and decrease hospital visits.
Researchers found that IVMT-Rx-4 selectively blocks the function of the MDA-9/Syntenin protein, limiting tumor growth and eliminating therapy resistance in preclinical cancer models. The study suggests a new targeted treatment option for head and neck squamous cell carcinoma.
A recent study published in Cancer Research found that sildenafil, the active ingredient in Viagra, can restrict cancer metastasis by limiting cancer cells' access to cholesterol. Combining sildenafil with statins may enhance this effect, potentially improving survival rates among cancer patients.
A phase 3 clinical trial found that adding high-dose vitamin D to standard treatment did not improve progression-free survival in patients with metastatic colorectal cancer. Median progression-free survival was 11.8 months with high-dose vitamin D compared to 10.3 months with standard dose.
A Rice University research team created prostate cancer cells that can survive high-force moments in the body, a process known as mechanoresistance. The study found that a gene called CALB2 plays a key role in this ability, with increased expression linked to metastatic cancer.
Researchers at UIC identified KCNMB1, an ion channel protein that helps regulate cell movement. Activating this pathway increases cell stiffness, making cancerous cells more susceptible to immune attack. The discovery points to a promising new therapeutic target for metastatic cancer.
A study reveals ADAR1p110 drives HCC metastasis by regulating microRNA biogenesis, particularly through post-transcriptional regulation of miR-451a. This blockade suppresses mature miR-451a, leading to increased TUBA1A expression and enhanced tumor cell migration and invasion.
A cohort study reveals that colorectal cancer treatment delays are associated with increased metastasis risk. This finding highlights the need for integrated care and tailored benchmarks for treatment initiation to improve timely and equitable care.
A study published in Cancer Cell identified a six-gene signature in microscopic colorectal cancer liver metastases that may help predict recurrence after treatment. The findings suggest these tiny tumor deposits could serve as a tissue-based marker of residual cancer cells, recurrence risk and chemotherapy resistance.
Researchers at the University of Turku have developed a reliable laboratory model to study BAP1-deficient melanomas, which are resistant to immunotherapies. The new tool could lead to novel immunotherapy combinations for aggressive melanomas.
Scientists have discovered that fat tissue can be hijacked by tumor cells, leading to its spread throughout the body. The fat tissue releases adipomes, which deliver a 'lipid code' that reprograms cancer cells, boosting their growth and invasiveness.
Researchers found that radiation therapy not only targets tumor cells but also activates immune pathways to make tumors more receptive to immunotherapy. The study suggests that radiation-immunotherapy combination strategies could improve patient outcomes by reshaping the surrounding immune landscape and recruiting T cells.
The Pew Charitable Trusts and the Alexander and Margaret Stewart Trust announced the selection of five early-career scientists to pursue four-year grants in cancer research. The scholars will investigate big questions about cancer development, diagnosis, and treatment.
A team of researchers has identified a previously unknown vulnerability in KRAS-mutated pancreatic cancer cells, making them susceptible to necroptosis. Blocking the tumor cells' defense mechanism by inhibiting caspase-8 leads to significant cell death and reduced tumor growth.
Two new UH CPRIT grants will accelerate lung cancer prevention, diagnosis, and treatment. Researchers aim to develop new mRNA-based immunotherapies and a next-generation blood test for precise lung cancer detection.
Researchers identify key mechanisms and molecular targets to prevent tumor progression in patients with rhabdomyosarcoma, a rare soft tissue cancer affecting young children. Two new treatment possibilities have been highlighted, targeting the IRE1α-XBP1 signaling axis and protein TAK1.
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
Researchers discover that breast cancer cells exploit protective systems in bone marrow to remain dormant, using Notch2 signaling and genes like CXCR4 and TIE2. This dormancy allows cells to reactivate years later, leading to secondary tumors.
A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...
Research identifies HMGB3 as a critical driver of malignancy in ESCC, enhancing cell proliferation, migration, and invasion. TGIF2-mediated HMGB3 overexpression drives the oncogenic cascade through the TLR3/TGF-β axis, promoting tumor progression and metastasis.
Researchers found that increasing ADAR2 expression in osteosarcoma cells forces them to differentiate, slowing growth and invasive capacity. The treated cells began producing mineralized matrix, a hallmark of mature bone tissue. In mice, ADAR2-restored tumors were smaller and less invasive.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
Dr. Marcus Ruscetti receives the prize to study senescence and its impact on immune responses in cancer metastasis. The funding will help him develop novel treatments targeting senescent cells.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
A team of researchers has developed a 'tumor-on-a-chip' system designed to recreate the complex environment surrounding pancreatic tumors. The system, which combines patient-derived organoids with microfluidic technology, closely mimics the behavior of human pancreatic tumors and demonstrates potential for studying immune responses.
A new paradigm shift in cancer research defines valid primary study endpoints for oligometastatic disease, focusing on treatment-free time and minimal side effects. The consensus paper establishes two new metrics: STFS (Start or Switch of Systemic Therapy–Free Survival) and pPFS (polymetastatic Progression–Free Survival), which capture...
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A new study has identified the WWOX protein as a molecular guardian that prevents common skin tumors from undergoing a dangerous metamorphosis and spreading to other parts of the body. The loss of this protein allows cancer cells to transform into more aggressive, invasive forms.
A research team has identified signalling molecules called Netrins and the corresponding receptor Frazzled/Deleted in Colorectal Cancer that control when individual cells separate from the tumour and migrate. These mechanisms can enable cancer cells to colonize new tissue, a major factor in metastasis.
Researchers at VCU Massey Comprehensive Cancer Center developed a targeted therapy that effectively prevents prostate tumors from spreading to the bone. The small molecule inhibitor IVMT-Rx-4 blocks the function of MDA-9/Syntenin, preventing tumor growth and improving survival in models with bone metastasis.
Researchers found that targeting MD2 could reduce tumor growth in a mouse model of prostate cancer bone metastasis. High MD2 expression was associated with metastasis, immune suppression, and increased resistance to PARP inhibitor therapy.
Researchers found that the three-drug combination increased autophagosome formation and autophagic flux in uveal melanoma cells, killing them via enhanced autophagy. The study suggests a potential therapeutic approach for treating metastatic uveal melanoma, particularly in liver-targeted disease.
A study by UC San Diego researchers reveals TYK2's role in preventing cancer spread and highlights need for enhanced screening in patients treated with TYK2 inhibitors. Understanding mechanotransduction can provide new avenues for treatment and improve breast cancer outcomes.
A new platform called ATLAS enables researchers to generate large quantities of cancer cell clusters that accurately model metastasis. Using ATLAS, the Rice team gained insights into the mechanisms that enable cancer clusters to survive in the bloodstream during the metastatic process.
A study found that tumor DNA in patients' blood can predict whether breast cancer will return, especially after neoadjuvant treatment. Patients with detectable DNA at the end of treatment were 3.5 times more likely to relapse during follow-up.
A recent study has revealed that brain tumors use a protein called MIF to reprogram immune cells, such as macrophages and microglia, to drive tumor growth. The researchers have identified a drug, ibudilast, which can block this process, slowing metastasis in animal models and fresh patient samples.